Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01488630 · ClinicalTrials.gov registry record · Phase 2
Substance Treatment and HIV Testing and Referral System
A Phase 2 study of Substance Abuse, sponsored by Polaris Health Directions.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT01488630 is a Phase 2 study of Substance Abuse that has completed, run by Polaris Health Directions. The registered enrollment target is 60 participants, below the 5,259-participant average among 58 other Substance Abuse trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01488630, a Phase 2 study of Substance Abuse, has completed, sponsored by Polaris Health Directions.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The lack of substance screening and referral in healthcare settings is a significant problem with far-reaching consequences, including excess morbidity, premature mortality, and inflated healthcare costs. An easy to use, time-efficient referral system is needed to address this problem. The Substance Treatment Referral Systems (STaRS), a computer assisted screening and referral system, was developed to meet this need. STaRS Phase I demonstrated the feasibility of STaRS to meet this need. All aims and evaluation goals of the Phase I study were met or exceeded. The purpose of the Phase II research is to demonstrate the clinical utility and commercial viability of STaRS. Specific Aims of Phase II are: 1. Integrate STaRS with the Epic electronic health record used in the Cooper Health System in Camden, N.J. 2. Document STaRS' effectiveness in (a) increasing the number of referrals provided for substance abuse treatment and HIV screening, and (b) increasing the proportion of patients that initiate specialty treatment. 3. Evaluate clinician acceptance and impact upon revenue generation. The research will be conducted at Cooper Family Medicine (CFM) department of Cooper University Hospital in New Jersey. We will determine the rate of referrals and treatment initiation for 3,500 adult patients treated during treatment as usual (the time before STaRS is implemented at CFM) as well as 3,500 adult patients treated after the introduction of STaRS. Patients will be asked about the referral initiation process, and CFM healthcare providers will be asked to evaluate the system from a clinical and administrative prospective. Finally, billing records will be reviewed during the STaRS implementation to determine whether STaRS impacted revenue for the practices.
Conditions Studied
Interventions
- OTHER STaRS
Study Locations (1)
New Jersey
- Cooper Family Medicine - Camden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01488630
The ClinicalTrials.gov registry entry for NCT01488630 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,259-participant average among 58 other Substance Abuse trials with a reported enrollment target (99% lower). The listed sponsor is Polaris Health Directions, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Substance Abuse appearing as the primary indexed condition, and to 1 intervention - of which STaRS is the first listed.
NCT01488630 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT01488630 about?
NCT01488630 is a clinical study titled "Substance Treatment and HIV Testing and Referral System". The lack of substance screening and referral in healthcare settings is a significant problem with far-reaching consequences, including excess morbidity, premature mortality, and inflated healthcare costs. An easy to use, time-efficient referral system is needed to address this problem. The Substance...
What is the current status of trial NCT01488630?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2011-12. Estimated completion is 2013-03.
What conditions does trial NCT01488630 study?
This clinical trial studies the following conditions: Substance Abuse.
What interventions are being tested in trial NCT01488630?
The interventions under investigation include: STaRS (OTHER).
Who is sponsoring clinical trial NCT01488630?
This trial is sponsored by Polaris Health Directions, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01488630 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enhancing Prevention Capacity With Developmental Assets and Getting to Outcomes
COMPLETED · Phase 2
-
Evaluation of Treatments for Homeless Youths
COMPLETED · Phase 2
-
Study of Medical Treatment for Methamphetamine Addiction
COMPLETED · Phase 2
-
Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial
COMPLETED · Phase 2
-
Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals
COMPLETED · Phase 2
-
Building Outcomes With Observation-Based Supervision: An FFT Effectiveness Trial
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.